MTOR and hepatocellular carcinoma: For example, HCC tumors harboring oncogenic PI3K-MTOR mutations had worse outcomes on sorafenib treatment, while the presence of an activating WNT/β-catenin alterations was associated with innate resistant to immune checkpoint inhibitors [8].